US$ 29.86
foxo4 dri human trial senolytic Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4-DRI induces keloid senescent fibroblast
Description
This synthetic peptide is intricately designed, with a molecular structure derived from the FOXO4 transcription factor and composed of a D-amino acid sequence

Systematic preparation supports reliable results during clinical research activities

Left plot: experiment 1

This identified "LLD factor" as essential for the bacteria's growth